BioWorld

Jan. 31, 2003

View Archived Issues

FDA Response Letter Seen As Positive Sign For MedImmune

A complete response letter from the FDA regarding FluMist has elicited a positive reaction at MedImmune Inc., which also reported record revenue as part of its fourth-quarter and year-end earnings. (BioWorld Today) Read More

Affymetrix Signs $70M GeneChip Deal With Roche Diagnostics

Read More

As West Nile Encephalitis Virus Blankets North America, Authors Seek To Disarm Immune Attacks

Read More

Corixa, GSK Changing Terms Of Cancer Vaccine Agreement

Read More

Biotech Reps Square Off With Feds Over Reimbursement Rates

Read More

Elan Continues Divestiture With Product Sales To King

Read More

Other News To Note

Read More